EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO’s SNAP technology has gained regulatory approval for Phase I/II studies
SNAP-based EuBiologics EuCorVac-19 gains regulatory approval for Phase I/II trials in Korea EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a
POP BIO announces $3M investment and JV formation with Eubiologics for the development of an RSV vaccine POP Biotechnologies, Inc. (POP BIO), a preclinical stage biotechnology
POP Biotechnologies awarded $599,897 NIH contract for HIV vaccine development in collaboration with Scripps Research BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,897,
POP Biotechnologies awarded $399,917 NIH-NCI Phase I STTR in collaboration with Roswell Park BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $399,917 Phase I
